Get the Stockscreener App
182.09
0.08%
0.15
Biogen Inc stock is traded at $182.09, with a volume of 566.36K.
It is up +0.08% in the last 24 hours and up +22.10% over the past month.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
See More
Previous Close:
$181.94
Open:
$182.07
24h Volume:
566.36K
Relative Volume:
0.32
Market Cap:
$26.71B
Revenue:
$9.61B
Net Income/Loss:
$1.53B
P/E Ratio:
17.42
EPS:
10.453
Net Cash Flow:
$1.85B
1W Performance:
+3.87%
1M Performance:
+22.10%
6M Performance:
+42.78%
1Y Performance:
+13.93%
1-Day Range:
$180.69
$182.74
1-Week Range:
$175.57
$185.17
52-Week Range:
$110.03
$185.17
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
182.09 | 26.69B | 9.61B | 1.53B | 1.85B | 10.45 |
|
LLY
Lilly Eli Co
|
1,075.47 | 988.41B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
206.92 | 500.07B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
227.70 | 402.36B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
130.40 | 250.29B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
104.83 | 259.69B | 63.90B | 19.05B | 13.05B | 7.5596 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-25 | Upgrade | Stifel | Hold → Buy |
| Sep-25-25 | Initiated | Jefferies | Buy |
| Jul-21-25 | Resumed | Truist | Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-04-25 | Downgrade | Argus | Buy → Hold |
| Feb-11-25 | Initiated | Bernstein | Mkt Perform |
| Jan-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-18-24 | Downgrade | Needham | Buy → Hold |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-31-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
Biogen, Eisai File In Japan To Make Leqembi A Weekly At-Home Alzheimer's Shot - Benzinga
Nvidia, Microsoft, Apple, Zillow, Biogen: What brokers said this week - Proactive financial news
Biogen shares could climb on Leqembi uptake – Jefferies - Proactive financial news
Biogen, Eisai Seek Japan Approval for Alzheimer's Drug At-Home Injection - MarketScreener
Jefferies Adjusts Price Target on Biogen to $210 From $190, Maintains Buy Rating - MarketScreener
Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan - Biogen
Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan - GlobeNewswire Inc.
Will Biogen Inc. stock benefit from sector rotationJuly 2025 Highlights & Weekly High Return Opportunities - moha.gov.vn
How Recent Developments Are Rewriting the Story for Biogen - Yahoo Finance
Total debt per share of Biogen Inc. – DUS:IDP - TradingView
Health Plans Defend Renewed Biogen MS Drug Scheme Suit - Law360
Biogen's $50 Million Immunology Power Move: Are Oral Peptides The Future? - Smartkarma
Wilson Sonsini Advises Dayra Therapeutics on Strategic Collaboration with Biogen Inc. - Wilson Sonsini
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status - ACN Newswire
Avoiding Lag: Real-Time Signals in (BIIB) Movement - news.stocktradersdaily.com
J&J Halts Alzheimer's Trial After Drug Fails To Slow Clinical DeclineJohnson & Johnson (NYSE:JNJ) - Benzinga
Biogen Inks Research Deal With Dayra to Boost Immunology Pipeline - TradingView
Biogen (BIIB) Advances Alzheimer's Treatment with FDA Submission - GuruFocus
Eisai Completes Rolling Submission to U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status - PR Newswire
Versant Ventures Announces Launch of Dayra Therapeutics With Foundational Biogen Partnership - MarketScreener
Why Biogen (BIIB) Is Up 7.4% After Announcing Dayra Immunology Collaboration and Pipeline Expansion - simplywall.st
Versant-backed start-up Dayra emerges with Biogen partnership: Deals Report - biocentury.com
BIIBLEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia - mx.advfn.com
Biogen Joins The Macrocycle Melee With Dayra Tie-Up - Citeline News & Insights
Novo Nordisk Stock Falls. Why Its Alzheimer’s Trial News Is Hitting Shares. - Barron's
Biogen strikes deal with Versant-backed biotech to expand immune portfolio - BioPharma Dive
Key facts: Biogen shares rise 5% after Rybelsus trial failure; partners with Dayra - TradingView
How Do Investors Really Feel About Biogen Inc? - Benzinga
Health Care Stocks Edge Up As Biotech Shines And Eli Lilly Gets A Nod - Finimize
Dayra Therapeutics secures Biogen partnership and $70M before officially opening its doors - The Business Journals
Biogen partners with Dayra to develop oral macrocyclic peptides By Investing.com - Investing.com Nigeria
Why Is Biogen Stock Trading Higher After Semaglutide Alzheimer's Data? - Sahm
Novo Nordisk’s Alzheimer’s Trials Were a Long Shot. Their Failure Is Still Hitting the Stock. - Barron's
Biogen and Dayra in deal over oral macrocyclic peptides - The Pharma Letter
Analysts, investors say Alzheimer's miss adds to Novo's challenges, but fundamentals intact - Reuters
Biogen stock hits 52-week high at 177.37 USD By Investing.com - Investing.com Canada
Biogen to gain from Novo Nordisk Alzheimer’s failure, says Jefferies By Investing.com - Investing.com Canada
Biogen (BIIB) Partners with Dayra Therapeutics to Develop Oral M - GuruFocus
Biogen, Dayra Therapeutics Collaborate to Develop Oral Macrocyclic Peptides - MarketScreener
Novo Nordisk’s Alzheimer’s Trials Always Were a Long Shot. The Stock Is Falling Anyway. - Barron's
Biogen, Dayra Therapeutics Partner To Develop Oral Macrocyclic Peptides For Immunological Diseases - Nasdaq
Novo Nordisk shares plunge as oral semaglutide Alzheimer’s trial fails to show clinical benefit - TradingView
Biogen, Dayra Therapeutics to collaborate on developing oral macrocyclic peptides - MarketScreener
Biogen partners with Dayra to develop oral macrocyclic peptides - Investing.com
Biogen rises after Novo Nordisk's drug fails to meet main goal in Alzheimer's trials - TradingView
Biogen, Dayra Therapeutics To Collaborate On Developing Oral Macrocyclic Peptides - TradingView
Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions - Biogen
Biogen (Nasdaq: BIIB), Dayra to Develop Oral Macrocyclic Peptides for Immunology - Stock Titan
Biogen Reaches Research Deal With Dayra in Immunology Push - Bloomberg.com
Eli Lilly stock falls, Biogen rises after Novo’s Alzheimer’s trial failure - Investing.com Canada
Biogen wins U.S. EU review for higher dose version of SMA drug marketed with Ionis - MSN
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Biogen Inc Stock (BIIB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Godbout Sean | Chief Accounting Officer |
Oct 02 '25 |
Option Exercise |
0.00 |
26 |
0 |
503 |
| Singhal Priya | Head of Development |
Aug 29 '25 |
Option Exercise |
0.00 |
1,669 |
0 |
7,096 |
| Singhal Priya | Head of Development |
Sep 02 '25 |
Sale |
133.55 |
517 |
69,045 |
5,772 |
0.30%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):